ClinicalTrials.gg
WithdrawnNCT03978494TODAYUpdated Sep 17, 2019

Study to Compare Pharmacokinetics of Tacrolimus Prolonged-release (PR) Capsules and Advagraf® PR Capsules in Stable Kidney Transplant Patients.

A Phase 1 interventional study of Advagraf® and Generic tacrolimus in Kidney Transplant, sponsored by Sandoz. Withdrawn at 13 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-09-17.

Sponsored by Sandoz (formerly part of Novartis) · Phase 1, Interventional, and Other

Why this study was withdrawn
company decision

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Study to compare pharmacokinetics of tacrolimus prolonged-release (PR) capsules and Advagraf® PR capsules in stable kidney transplant patients.

Read the detailed description

Initially, patients will enter a short screening period, and those who continue to meet the inclusion and exclusion criteria will be randomized to receive either test or reference medicinal product in Period 1. In period 2 they will switch to the other formulation. During the whole treatment period four full-pharmacokinetics profiles will be established.

02

Conditions studied

  • Kidney Transplant

Keywords

  • Kidney transplant; Renal transplant
03

In context

Lead sponsor

Sandoz is the lead sponsor of 139 studies on the registry; none are open to participants now.

Of its 11 completed or terminated interventional studies of FDA-regulated products, 6 (55%) have results posted.

First submitted before Sandoz left Novartis.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female patients aged ≥18 years;
  • Patients with a (BMI) included in the interval [18.5-33.0] kg/m²;
  • Patients who received a primary kidney transplant at least 12 months prior to study entry

Exclusion criteria

Exclusion Criteria:

  • Evidence or suspicion of ongoing or persistent, acute or chronic rejection;
  • Requirement for dialysis within the six months prior to study entry;
  • (GFR) \<30 mL/min
  • Pregnant or breastfeeding women, confirmed by a positive human chorionic gonadotropin (hCG) laboratory test;
  • Intolerance to tacrolimus, (including lactose, fructose or galactose), or similar products;
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Period 1: Advagraf®; Period 2: Generic tacrolimus

    In Period 1 patients will receive branded tacrolimus (Advagraf®) orally once-a-day and in Period 2 patients will receive the generic tacrolimus (Sandoz) orally once-a-day.

    Drug: Advagraf® · Drug: Generic tacrolimus

  • Experimental
    Period 1: Generic tacrolimus; Period 2: Advagraf®

    In Period 1 patients will receive the generic tacrolimus (Sandoz) orally once-a-day and in Period 2 patients will receive branded tacrolimus (Advagraf®) orally once-a-day.

    Drug: Advagraf® · Drug: Generic tacrolimus

Interventions

  • Advagraf®1 mg and 5 mg prolonged-release hard capsules once daily (reference medicinal product).

  • Tacrolimus 1 mg and 5 mg prolonged release hard capsules (Sandoz) once daily (test medicinal product)

06

What researchers measure

Primary outcomes

  1. AUC(0-τ)ss

    Area under the whole blood concentration curve during a dosage interval (τ=24 hours) at steady state

    Time frame: Day 21 of each treatment period

  2. Cmax,ss

    Maximum whole blood concentration at steady state

    Time frame: Day 21 of each treatment period

Secondary outcomes

  1. AUC(0-τ)ss

    Area under the whole blood concentration curve during a dosage interval (τ=24 hours) at steady state

    Time frame: Day 14 of each treatment period

  2. Cmax,ss

    Maximum whole blood concentration at steady state

    Time frame: Day 14 of each treatment period

  3. Cmin,ss

    Minimum whole blood concentration at steady state

    Time frame: Days 14 and 21 of each treatment period

  4. Cτ,ss

    Concentration at the end of the dosing interval at steady state

    Time frame: Days 14 and 21 of each treatment period

  5. Cav

    Average concentration during a dosing interval: AUC(0-τ)/τ

    Time frame: Days 14 and 21 of each treatment period

  6. Tmax,ss

    Time to reach maximum (peak) plasma concentration at steady state

    Time frame: Days 14 and 21 of each treatment period

  7. AUC(0-τ)ss coefficient of variation

    Intra-patient pharmacokinetics variability evaluated by calculating AUC(0-τ)ss coefficient of variation

    Time frame: Days 14 and 21 of each treatment period

  8. Cmax,ss coefficient of variation

    Intra-patient pharmacokinetics variability evaluated by calculating Cmax,ss coefficient of variation

    Time frame: Days 14 and 21 of each treatment period

  9. % Fluctuation

    Degree of fluctuation of the analyte concentration levels over one dosing interval: 100\*(Cmax,ss - Cmin,ss)/Cav.

    Time frame: Days 14 and 21 of each treatment period

  10. %Swing

    Degree of change of the analyte concentration levels over one dosing interval: 100\*(Cmax,ss - Cτ,ss)/Cτ,ss.

    Time frame: Days 14 and 21 of each treatment period

07

Study locations

13 sites
  • Sandoz Investigative Site
    Grenoble, France
  • Sandoz Investigative Site
    Limoges, France
  • Sandoz Investigative Site
    Nantes, France
  • Sandoz Investigative Site
    Strasbourg, France
  • Sandoz Investigative Site
    Suresnes, France
  • Sandoz Investigative Site
    Toulouse, France
  • Sandoz Investigative Site
    Tours, France
  • Sandoz Investigative Site
    Berlin, Germany
  • Sandoz Investigative Site
    Bochum, Germany
  • Sandoz Investigative Site
    Essen, Germany
  • Sandoz Investigative Site
    Hannover, Germany
  • Sandoz Investigative Site
    Kaiserslautern, Germany
  • Sandoz Investigative Site
    Kiel, Germany
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Sep 2019; primary completion for May 2020, 8 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 5, 2019
First posted
Jun 7, 2019
StartEst.
Sep 2, 2019
Primary completionEst.
May 3, 2020
CompletionEst.
May 3, 2020
Last update
Sep 17, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 17, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03978494
Lead sponsor
Sandoz
Responsible party
Sponsor
First posted
Jun 7, 2019
Start date
Sep 2, 2019 (estimated)
Primary completion
May 3, 2020 (estimated)
Completion
May 3, 2020 (estimated)
Last update
Sep 17, 2019

Study contacts

Sandoz
study director · Sandoz

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tacrolimus

Start the discussion